{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:31Z","timestamp":1791919051655,"version":"4.3.4"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Colorectal cancer is the third most common malignant disease and the second leading cause of death worldwide. Previous studies showed improved bioavailability and cytotoxicity of ginsenoside-modified nanostructured lipid carrier containing curcumin (G-NLC) in human colon cancer cell lines. This study aimed to evaluate the safety and tolerability with long-term survival rates in patients with colorectal cancer with unresectable metastases after treatment with first-line bevacizumab\/FOLFIRI (folinic acid, bolus\/continuous fluorouracil, and irinotecan) in combination with a dietary supplement of G-NLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study was a prospective, observational, single-group analysis. The enrolled patients had colorectal cancer with unresectable metastases and were administered bevacizumab and FOLFIRI in combination with daily oral G-NLC as first-line treatment. Overall survival, progression-free survival, tumor response, and adverse events were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 44 patients were enrolled between 2015 and 2019. The median age was 65 (range 45-81) years and the sex ratio was 31:13 (male:female). The primary tumor locations were the colon (31 patients) and rectum (13 patients). The metastatic sites included, liver only (n\u2009=\u200920), lung only (n\u2009=\u20096), both liver and lung (n\u2009=\u200912), and others (n\u2009=\u20096). The median duration of curcumin supply was 7.9 (range 0.9-16.6) months. The most common grade 3 or higher adverse events were neutropenia (n\u2009=\u200915, 34.1%), followed by nausea (n\u2009=\u20094, 9.1%) and vomiting (n\u2009=\u20094, 9.1%). Within the median follow-up period of 22.8\u2009months, the median overall survival was 30.7\u2009months, and the median progression-free survival was 12.8\u2009months. None of the patients achieved complete response (CR); however, 9 patients showed partial response (PR), and 3 patients underwent conversion surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Bevacizumab\/FOLFIRI with G-NLC as first-line chemotherapy in patients with colorectal cancer with unresectable metastases presented comparable long-term survival outcomes with acceptable toxicity outcomes. Additional randomized controlled studies are needed to establish definitive conclusions regarding this new regimen for metastatic colorectal cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15347354221105498","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:53:22Z","timestamp":1655096002000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":39,"title":["Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-9536","authenticated-orcid":false,"given":"Youngbae","family":"Jeon","sequence":"first","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Kyu","family":"Yoo","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Gachon University, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-8041","authenticated-orcid":false,"given":"Jeong-Heum","family":"Baek","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"bibr1-15347354221105498","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.06.012"},{"key":"bibr3-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.014"},{"key":"bibr4-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.113"},{"key":"bibr5-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70330-4"},{"key":"bibr6-15347354221105498","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072364"},{"key":"bibr7-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07256-8"},{"key":"bibr8-15347354221105498","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S61823"},{"key":"bibr9-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-017-0930-1"},{"key":"bibr10-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1295-1"},{"key":"bibr11-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1467-z"},{"key":"bibr12-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr13-15347354221105498","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed June 14, 2010."},{"key":"bibr14-15347354221105498","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00152"},{"key":"bibr15-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0024"},{"key":"bibr16-15347354221105498","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.9.1.10392"},{"key":"bibr17-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1159\/000441148"},{"key":"bibr18-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/nxz029"},{"key":"bibr19-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw206"},{"key":"bibr20-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"bibr21-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01140-9"},{"key":"bibr22-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr571"},{"key":"bibr23-15347354221105498","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.46.1.2"},{"key":"bibr24-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1177\/0885328215594479"},{"key":"bibr25-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0573-4"},{"key":"bibr26-15347354221105498","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-018-1495-3"},{"key":"bibr27-15347354221105498","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27441"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354221105498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15347354221105498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354221105498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:16:45Z","timestamp":1777454205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15347354221105498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"alternative-id":["10.1177\/15347354221105498"],"URL":"https:\/\/doi.org\/10.1177\/15347354221105498","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"15347354221105498"}}